These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

749 related items for PubMed ID: 25501326

  • 1. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L, Cervino AR, Michieletto S, Saibene T, Orvieto E, Bozza F, Ghiotto C.
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [Abstract] [Full Text] [Related]

  • 2. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
    Tiling R, Linke R, Untch M, Richter A, Fieber S, Brinkbäumer K, Tatsch K, Hahn K.
    Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
    [Abstract] [Full Text] [Related]

  • 3. Predicting Response to Neoadjuvant Chemotherapy Using 18F FDG PET-CT in Patients with Locally Advanced Breast Cancer.
    Hulikal N, Gajjala SR, Kalawat T, Kadiyala S, Kottu R.
    Asian Pac J Cancer Prev; 2020 Jan 01; 21(1):93-98. PubMed ID: 31983170
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
    Mezi S, Primi F, Capoccetti F, Scopinaro F, Modesti M, Schillaci O.
    Int J Oncol; 2003 Jun 01; 22(6):1233-40. PubMed ID: 12738988
    [Abstract] [Full Text] [Related]

  • 6. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
    García Vicente AM, Amo-Salas M, Relea Calatayud F, Muñoz Sánchez Mdel M, Pena Pardo FJ, Jiménez Londoño GA, Álvarez Cabellos R, Espinosa Aunión R, Soriano Castrejón Á.
    Clin Nucl Med; 2016 Jul 01; 41(7):e313-22. PubMed ID: 26953659
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP, David S, Alamgeer M, Ganju V.
    Int J Radiat Oncol Biol Phys; 2015 Sep 01; 93(1):111-7. PubMed ID: 26279029
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C, Kuemmel S, Hoffmann O, Stahl AR, Kimmig R, Otterbach F, Ladd S, Koeninger A, Forsting M, Bockisch A, Antoch G, Heusner TA.
    Acta Radiol; 2012 Jul 01; 53(6):628-36. PubMed ID: 22761341
    [Abstract] [Full Text] [Related]

  • 11. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
    Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB.
    Cancer; 1999 Jun 01; 85(11):2410-23. PubMed ID: 10357412
    [Abstract] [Full Text] [Related]

  • 12. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK, Yoo IR, Kim SH, Park SY, O JH, Kang BJ.
    Acta Radiol; 2018 Jan 01; 59(1):41-49. PubMed ID: 28427271
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.
    Cancer; 2013 Jun 01; 119(11):1960-8. PubMed ID: 23504954
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E.
    J Nucl Med; 2015 Jun 01; 56(6):824-31. PubMed ID: 25883123
    [Abstract] [Full Text] [Related]

  • 20. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
    Weber MA, Bender K, von Gall CC, Stange A, Grünberg K, Ott K, Haberkorn U, Kauczor HU, Zechmann C.
    J Gastrointestin Liver Dis; 2013 Mar 01; 22(1):45-52. PubMed ID: 23539390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.